Intercept Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Fibrosis of the liver, the process of chronic scarring leading to cirrhosis, can result from viral infections such as hepatitis, as well as alcoholism and obesity-diverse factors that historically have made it difficult to treat and impossible to prevent, much less reverse. But that's what Intercept Pharmaceuticals Inc. believes it can do with its lead compound, INT-747.